Tagged with PPD

Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…

Mexico Cecilia Moreno, from the PPD™ clinical research business of Thermo Fisher Scientific, highlights Mexico’s growing role in clinical research, supported by regulatory advancements and a skilled workforce. Moreno emphasizes the potential for expanding clinical trials in Mexico, enhancing patient access to innovative therapies, and leveraging the country’s strategic advantages in…

France Nathalie Giraud, director of integrated monitoring investigator services & head of France at PPD, breaks down the strengths and weaknesses of the French clinical trials environment and stresses the importance of France in PPD’s overall operations. She also explains how the contract research organization is catering to the needs of…

Tunisia Jade Salhab, senior private sector development specialist at World Bank Tunisia, discusses the impact of the public-private dialogues initiated by his organization in Tunisia, and the additional measures needed to improve healthcare outcomes in Tunisia The World Bank, in response to a request from the government of Tunisia, facilitated a…

Bulgaria Hristo Sabev, director of clinical management for PPD in Bulgaria, shares an interesting overview of clinical research in Bulgaria and highlights PPD’s commitment as one of the leading CROs in the country. PPD has a quite unique footprint in the country due to the acquisition of AbCRO back in 2009.…